Clinical Trial

Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid
Protocol Amendment History 6 changes
notable Trial sites expanded: 24 -> 28 locations 2026-08-06
notable Trial sites expanded: 15 -> 20 locations 2026-07-21
notable Trial sites expanded: 8 -> 11 locations 2026-07-10
notable Trial sites expanded: 5 -> 8 locations 2026-07-07
notable Trial sites expanded: 2 -> 5 locations 2026-07-01
critical Recruitment opened 2026-06-24
Trial Details
NCT Number NCT07661056
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions Graves Disease
Enrollment 300 participants
Start Date 2026-06-26
Primary Completion 2028-01 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-07